Natixis Advisors LLC Raises Stake in Charles River Laboratories International, Inc. $CRL

Natixis Advisors LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 114,357 shares of the medical research company’s stock after purchasing an additional 9,397 shares during the period. Natixis Advisors LLC owned approximately 0.23% of Charles River Laboratories International worth $22,812,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of CRL. Jones Financial Companies Lllp grew its position in Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new position in Charles River Laboratories International during the 1st quarter worth $418,000. American Century Companies Inc. grew its position in Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the last quarter. Brown Advisory Inc. grew its position in Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on CRL shares. Evercore reissued an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. UBS Group raised their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Finally, Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $208.50.

Charles River Laboratories International Stock Down 2.3%

CRL stock opened at $181.46 on Friday. Charles River Laboratories International, Inc. has a one year low of $143.06 and a one year high of $228.88. The stock has a market capitalization of $8.74 billion, a PE ratio of -48.26, a price-to-earnings-growth ratio of 2.12 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The company has a fifty day moving average of $171.37 and a 200-day moving average of $181.57.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter last year, the business earned $2.34 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.